[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
25-Oct-2013

[ | E-mail ] Share Share

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
@jclinicalinvest

Synthetic vitamin D receptor ligands reduce murine kidney fibrosis

Vitamin D deficiency has been associated with kidney disease including fibrosis. Some studies have even suggested that treatment with vitamin D or vitamin D analogs can reduce renal fibrosis; however, the pathways targeted by vitamin D therapy are not completely understood. In this issue of the Journal of Clinical Investigation, Junn Yanagisawa and colleagues at the University of Tsukuba found that vitamin D binding to its receptor inhibited the TGF-β/SMAD signaling pathway and prevented renal fibrosis in mice. The authors then generated a synthetic ligand of the vitamin D receptor that, like vitamin D, reduced renal fibrosis; however, unlike vitamin D, this synthetic ligand did not promote hypercalcemia. In the accompanying commentary Joseph Bonventre suggests that synthetic ligands of the vitamin D receptor should be further studied as therapeutics for patients with fibrotic diseases.

###

TITLE:

A nonclassical vitamin D receptor pathway suppresses renal fibrosis

AUTHOR CONTACT:

Junn Yanagisawa

University of Tsukuba, Tsukuba, , JPN

Phone: 81-29-853-7320; E-mail: junny@agbi.tsukuba.ac.jp

View this article at: http://www.jci.org/articles/view/67804?key=e9b75812c32074994393

ACCOMPANYING COMMENTARY

TITLE:

Antifibrotic vitamin D analogs

AUTHOR CONTACT:

Joseph V. Bonventre

Brigham and Women's Hospital, Boston, MA, USA

Phone: 617-525-5966; Fax: 617-525-5965; E-mail: joseph_bonventre@hms.harvard.edu

View this article at: http://www.jci.org/articles/view/72748?key=c9aa266738ffedbb76ab



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.